Press release, Helsinki, 10 January 2025 at 9 AM (EET)
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that it has received an order for two NBS Systems 6 through a local distributor in Canada.
Nexstim’s NBS System 6 is cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) by Health Canada.
Mikko Karvinen, CEO of Nexstim, comments: “We are pleased to see a growing interest in navigated TMS in Canada, and being able to provide clinicians and their patients with state-of-the-art, personalized brain stimulation therapy, for relief of their symptoms.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com